Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

Chi V. Dang

Research output: Contribution to journalArticlepeer-review


In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)361-362
Number of pages2
JournalCancer Cell
Issue number5
StatePublished - Nov 6 2009

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology


Dive into the research topics of 'Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer'. Together they form a unique fingerprint.

Cite this